论文部分内容阅读
目的:探讨促血管生成素-2(Ang-2)在恶性肿瘤诊断中的应用价值。方法:对恶性肿瘤(观察组)136例与健康对照组46例,采用单克隆抗体透射比浊法检测血清中的Ang-2。采用ELISA法检测肝癌13例血清中的AFP和直肠癌10例血清中的CEA,并分别与Ang-2比较其阳性率。结果:观察组与对照组Ang-2的阳性率分别为28.7%和52.2%,两组比较,差异显著(P<0.05)。直肠癌患者血清Ang-2与CEA的阳性率均为50.0%;肝癌患者血清Ang-2与AFP的阳性率分别为46.2%和92.3%,AFP的阳性检出率显著高于Ang-2(P<0.05)。结论:Ang-2在恶性肿瘤中的检出率低,其临床应用价值有待进一步研究。
Objective: To investigate the value of angiopoietin-2 (Ang-2) in the diagnosis of malignant tumors. Methods: Thirty-six patients with malignant tumors (observation group) and 46 healthy controls were enrolled in this study. Serum Ang-2 levels were measured by turbidimetric method. ELISA method was used to detect CEA in serum of 13 patients with AFP and 10 patients with rectal cancer, and compared with the positive rate of Ang-2. Results: The positive rates of Ang-2 in observation group and control group were 28.7% and 52.2%, respectively. There was significant difference between the two groups (P <0.05). The positive rates of serum Ang-2 and CEA in rectal cancer patients were 50.0%. The positive rates of serum Ang-2 and AFP were 46.2% and 92.3% in hepatocellular carcinoma patients respectively. The positive rate of AFP was significantly higher than that of Ang-2 <0.05). Conclusion: The detection rate of Ang-2 in malignant tumors is low, and its clinical value needs further study.